Richard E. Royal, MD
Dr. Richard E. Royal is a surgical oncologist at Maine Medical Center Cancer Institute in Scarborough, Maine. His clinical interests include the care of patients with melanoma and skin cancers, as well as patients with rare gastrointestinal tumors, including malignant peritoneal mesothelioma. He has significant expertise in the use of hyperthermic intraperitoneal chemotherapy to deliver concentrated cancer-killing drugs directly to the surgical site following cytoreductive surgery.[1]
Education and Career
Dr. Royal earned his medical degree at the Oregon Health and Science University School of Medicine and completed an internship and residency in General Surgery at Wellspan Health/York Hospital. He then completed a research fellowship in Pediatric Surgery at the Cincinnati Children’s Hospital Medical Center, a fellowship in Allergy and Immunology at the National Institutes of Health Clinical Center, a fellowship in Surgery at the University of Rochester, and another at the University of Maryland. He completed his medical education and training with a fellowship in Complex General Surgical Oncology at the University of Texas M. D. Anderson Cancer Center in Houston, Texas.[1]
Dr. Royal served as a Senior Investigator at the National Cancer Institute and a tenured professor in surgery at M. D. Anderson Cancer Center before accepting his role at Maine Health.
Research
Dr. Royal’s research explores the use of immunotherapy in the treatment of melanoma and pancreatic cancer, and the benefits of interdisciplinary care of patients at a national level.[1]
His recent publications include:[2]
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Ben… Neal Bhutiani, Travis E Grotz, Seth J Concors, Michael G White, Beth A Helmink, Kanwal P Raghav, Melissa W Taggart, Karen A Beaty, Richard E Royal, Michael J Overman, …>; Annals of Surgical Oncology. 2024 Jan 1
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Kanwal Pratap Singh Raghav, Suyu Liu, Michael J. Overman, Anneleis Willett, Mark Knafl, Szu-Chin Fu, Anais Malpica, Seema Prasad, Richard E. Royal, Christopher P. Scal…>; Cancer Discovery. 2021 Jul 14
Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Anais Malpica, Elizabeth D. Euscher, Mario L. Marques-Piubelli, Maria C. Ferrufino-Schmidt, Roberto N. Miranda, Ralph Sams, Richard E. Royal, Kanwal Pratap Singh Ragha…>; The American Journal of Surgical Pathology. 2021 Jan 1
